- First funding allocated from the Medical Research Future Fund- $65.9 million
- MRFF to reach $20 billion in 2020/21
- NHMRC Funding continues to flatline
- ARC Funding is also in slow decline
Continue reading “Budget 2017-18 | Budget Summary”
Response to Budget 2017
Research Australia welcomes first grants issued by Medical Research Future Fund
Government delivers on promise to establish flow of funding into health and medical research $20 billion capital target to be achieved in 2020-21
After a long-fought campaign to bring the Medical Research Future Fund (MRFF) to reality, health and medical researchers have welcomed the first round of grants issued from the MRFF, as announced tonight in the Federal Budget. $65.9 million is available for 2016/17, with the detail of $25 million of this spending released tonight. Just as importantly, we now have a clear path to achieving the capital target of $20 billion, with the Budget papers revealing this target will be achieved in 2020-21.
Research Australia Director and CSL’s Senior Vice President of Research, Dr Andrew Nash, said the Budget announcement tonight confirmed the Government has begun to deliver on its promise to establish a consistent flow of funding for health and medical research.
“The grants announced tonight represent an important milestone in the establishment of this landmark source of funding for health and medical research.
Continue reading “Federal Budget 2017-18 | First grants issued by MRFF”
We have just got out of the Health Portfolio Federal Budget Lockup and here’s some early news on items affecting our sector.
We will provide you with more details around how the Federal Budget 2017-18 directly impacts health and medical research in the next few hours.
Bill Ferris AC, Chair of Innovation and Science Australia (ISA) recently floated the possibility of using major high-impact large scale projects to drive innovation. “In developing the 2030 Strategic Plan, we hope to identify one or more major, game-changing, initiatives with scale that can deliver significant direct and spill-over benefits to the innovation system and broader economy”.
Submissions for the 2030 Strategic Plan are due by the end of May. Now’s the time to to look into the future of science in this country, and you can shape the work you’re going to be doing for the next 20-30 years.
We are after BIG IDEA 2030 suggestions to include in our submission that will tweak the interest of Government and aim to position Australia as a global leader by 2030.
Need somewhere to start?
This week, the Prime Minister announced that the Temporary Work (Skilled) visa (subclass 457 visa) will be abolished and replaced with the completely new Temporary Skill Shortage (TSS) visa in March 2018.
The TSS visa program will be comprised of a Short-Term stream of up to two years and a Medium-Term stream of up to four years and will support businesses ‘in addressing genuine skill shortages in their workforce and will contain a number of safeguards which prioritise Australian workers.’
Continue reading “Temporary Work (Skilled) visa subclass 457 scrapped”
Joint statement on the Research & Development Tax Incentive
Don’t rip the guts out of Australian medical research commercialisation
Commercialisation of Australian medical research is under serious threat if the package of measures put by the ‘Ferris, Finkel, Fraser’ Review of the Research & Development (R&D) Tax Incentive is adopted and Australia’s medical technology, biotechnology, and pharmaceutical (MTP) sector is urging the Federal Government not to devastate Australia’s most innovative industry.
The R&D Tax Incentive is the most critical centre-piece program in the translation of Australia’s world-class research into treatments, cures, diagnostics, medical devices and vaccines. The program has been successful in helping attract more investment in R&D and fostering a strong Australian life sciences clinical trials and R&D sector.
Continue reading “Research & Development Tax Incentive”